Advertisement

Abstract

This chapter presents the global expectations of a stability program. It includes a thorough discussion of stability requirements of non-ICH regions as well as a discussion on how the climatic requirements are implied in the world. This comprehensive chapter gives an introduction of stability requirements for countries around the world. Discussions of World Health Organization (WHO) stability guidelines and Association of Southeast Asian Nations (ASEAN) stability requirements are also included.

Keywords

Relative Humidity Climatic Zone Safety Margin Partial Vapour Pressure Southern African Development Community 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Refernces

  1. 1.
    Schumacher P. 1972. Über eine für die Haltbarkeit von Arzneimitteln maβgebliche Klimaeinteilung. Pharm Ind 34:481–483.Google Scholar
  2. 2.
    Grimm W. 1986. Storage conditions for stability testing (Part 2). Drugs Made Ger 29:39–47.Google Scholar
  3. 3.
    Zahn M, et al. 2006. A risk-based approach to establish stability testing conditions for tropical countries. J Pharm Sci 95:946–965. Erratum 2007: J Pharm sci 96:2177CrossRefPubMedGoogle Scholar
  4. 4.
    Kottek M, et al. 2006. World map of Köppen–Geiger climate classification updated. Meteorol. Z. 15:259–263CrossRefGoogle Scholar
  5. 5.
  6. 6.
    Coordinated Universal Time (UTC) follows International Atomic Time (TAI) exactly except for an integral number of seconds, presently 32. These leap seconds are inserted on the advice of the International Earth Rotation Service (IERS) to ensure that, on average over the years, the sun is overhead within 0.9 s of 12:00:00 UTC on the meridian of Greenwich. UTC is thus the modern successor of Greenwich Mean Time, GMT, which was used when the unit of time was the mean solar day.Google Scholar
  7. 7.
    The basic elements of the project ERA-40 are described in: Uppala S. M., et al. 2005. The ERA-40 Reanalysis. Q J R Meteorological Soc 131:2961–3012. ERA-40 is a reanalysis of meteorological observations for the period from 1957 to 2002. A summary of the project is provided in ECMWF Newsletter Nr. 101 (pages 3–22) available via http://www.ecmwf.int/publications/newsletters/
  8. 8.
    Wexler A, et al. 1971. Vapor pressure equation for water in the range 0 to 100°C. J Res Natl Bur Stand (US) – A. Physics and Chemistry 75A:213–230.Google Scholar
  9. 9.
    Wexler A. 1976. Vapor pressure formulation for water in the range 0 to 100°C. A revision. J Res Natl Bur Stand (US) – A. Physics and Chemistry 80A:775–785.Google Scholar
  10. 10.
    Hardy R. 1998. ITS-90 Formulations for vapor pressure, frostpoint temperature, dewpoint temperature, and enhancement factors. Proceedings of the Third International Symposium on Humidity & Moisture, Teddington, London, England, AprilGoogle Scholar
  11. 11.
    Haynes JD. 1971. Worldwide virtual temperatures for product stability testing. J Pharm Sci 60:927–929.CrossRefPubMedGoogle Scholar
  12. 12.
    Who Expert Committee On Specifications For Pharmaceutical Preparations, 34th Report, Technical Report Series 863, Geneva 1996 http://whqlibdoc.who.int/trs/WHO_TRS_863_(p1-p98).pdf
  13. 13.
    World Health Organization. Expert Committee on Specifications for Pharmaceutical Preparations. 37th Report. Technical Report Series, No 908, p.13 (2003). http://whqlibdoc.who.int/trs/WHO_TRS_908.pdf
  14. 14.
    World Health Organization. 2002. “WHO Guidelines on stability testing” in: WHO Drug Information, 16(1): 35, on http://82.77.46.154/gsdldata/collect/whodruginfo/index/assoc/h2990e/h2990e.pdf#search=%22 vol%22
  15. 15.
  16. 16.
    Who Expert Committee On Specifications For Pharmaceutical Preparations (October 2005) 40th Report, Technical Report Series 937, Geneva 2006, p. 12, http://www.who.int/medicines/publications/pharmprep/TRS_937.pdf
  17. 17.
    Kopp S. 2006. Stability testing of pharmaceutical products in a global environment. Regul Aff J 16(5):291–294, http://www.who.int/medicines/areas/quality_safety/quality_assurance/RAJ2006WHOStability.pdf
  18. 18.
  19. 19.
  20. 20.
    During the 10th summit in Vientiane, Laos, on 29 November 2004, the leaders of the ASEAN member countries agreed to accelerate the economic integration. Standards and regulations will have to be harmonised earlier than the original target in order to eliminate import duties for products, including medicinal products. For more information see the Regul Aff J (Pharma) 16:111–112 (2005).Google Scholar
  21. 21.
    Slamet LS, et al. 2004. Stability testing for hot and humid climates. WHO Drug Inf 18: 113–116. http://82.77.46.154/gsdldata/collect/whodruginfo/index/assoc/s14174e/s14174e.pdf#search=%22 vol%22 Google Scholar
  22. 22.
    Resolution RE No. 398, dated 12 November 2004, published in the Official Gazette of the Union (Diário Oficial da União) on 16 November 2004, reported in Regul Aff J – Pharma, 2005, 16(2), 116Google Scholar
  23. 23.
    Resolution RE No. 1, dated 29 July 2005, published in the Official Gazette of the Union, Supplement to No. 146 – Section 1, Brasília – DF, on 1 August 2005.Google Scholar
  24. 24.
  25. 25.
    International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use – ICH harmonised tripartite guideline: “Stability testing of new drug substances and products” Q1A(R2) http://www.ich.org/LOB/media/MEDIA419.pdf
  26. 26.
    Zahn M. 1993. Stability testing in Arabic countries. Regul Aff J 4:558–561.Google Scholar
  27. 27.
    WHO EMRO 1994. Report on the Intercountry Workshop on the Validation of Expiry Dates of Drugs, Amman, Jordan, 29 March – 1 April 1993.Google Scholar
  28. 28.
    The Arab Union of the Manufacturers of Pharmaceutical and Medical Appliances (AUPAM) 1995 (updated in 2002). Arab Guidelines on Stability Testing of Pharmaceutical ProductsGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.3R Pharma Consulting GmbHKelternGermany

Personalised recommendations